Randomized trial compares biliary patency in patients with malignant biliary obstruction, indicating EUS-GBD is superior for longer patency.
Before matching, 294 patients were included (142 EUS-GBD; 152 EUS-CDS). After matching, 200 patients were analyzed (100 per group). Technical success was 100% for EUS-GBD and 97% for EUS-CDS (P = 0.25). Clinical success was 80.5% for EUS-GBD and 90.6% for EUS-CDS (P = 0.08). At 12 months, the probability of biliary patency was significantly higher with EUS-GBD than EUS-CDS (86.2% [95%CI 74.2%-92.9%] vs. 63.8% [95%CI 49.5-75.0]; P = 0.01). Biliary reintervention-free survival was significantly longer with EUS-GBD (log-rank, P < 0.001). Periprocedural AEs occurred in 7.0% vs. 10.0% (P = 0.61), delayed AEs in 27.0% vs. 30.0% (P = 0.75), and reintervention rates were comparable (23.0% vs. 26.0%; P = 0.74). Overall survival did not differ significantly (log-rank, P = 0.59). Conclusion In patients with MDBO after failed ERCP, EUS-GBD achieved higher 12-month biliary patency than EUS-CDS, with comparable rates of technical and clinical success, morbidity, reintervention, and overall survival.
No takes yet. Share an insight, caveat, or question.
Debourdeau et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: